Lyka Labs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
LYKALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lyka Labs Limited has filed its financial results for the period ended March 31, 2025 with the stock exchange. This is a routine compliance filing indicating that the company has reported its Q4 and full-year FY25 numbers. The headline itself does not disclose the actual financial figures, auditor opinion, or any specific commentary on performance. Retail investors will need to review the detailed results PDF or the company's investor presentation to assess revenue, profitability, margins, and any auditor observations.
No immediate price-moving information is contained in this brief filing notification. Investors should check the full results document for revenue growth/decline, profit trends, auditor remarks, and any exceptional items before drawing conclusions about the stock.